Page 1

03 20000 Interim report January - September 2021 AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system , such as Alzheimer's disease and pain - indications for which currently available treatment is very limited . The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms : NeuroRestore® , Alzstatin® and Painless . NeuroRestore consists of two symptomatic drug candi dates where the unique mechanism of action allows for multiple indications , including Alzheimer's disease , as well as cognitive disorders associated with traumatic brain injury , sleep apnea and Parkinson's disease . The Alzstatin platform focuses on developing disease - modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates . Painless is the company's research platform in the field of pain and contains two projects : ACD440 , which is a drug candidate in the clinical development phase for the treat ment of neuropathic pain , and TrkA - NAM , which targets severe pain in conditions such as osteoarthritis . AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase and is continually working on business development to find suitable outlicensing solutions with other pharmaceu tical companies . FNCA Sweden AB , +46 ( 0 ) 8-528 00 399 info@fnca.se , is the company's Certified Adviser . For more information , please visit www.alzecurepharma.com . AlzeCure